Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia

Abstract

Systemic bevacizumab was highly effective to treat chronic bleeding in HHT. Further study is needed to confirm the magnitude of benefit and further define optimal dosing, treatment duration and long-term safety.